BMO Lifts Starbucks Price Target After Earnings Beat

Starbucks (NASDAQ: SBUX) reported their fiscal third quarter results on July 27. The company beat the street estimate of $7.27 billion in revenue, with them reporting $7.49 billion in top-line revenue. Revenue grew 77.6% year over year, while gross profits grew more than 100% to $2.32 billion. Gross margins came in at 31% while operating margin came in at 19.9%. Net income came in at $1.15 billion while earnings per share were $0.97 for the quarter.

Off the beat, analysts raised their 12-month consensus price target to $131.11, from $126.37 which was the consensus target before the earnings were released. Kalinowski Equity has the street high price target of $148, while BZ Bank’s $95 price target is the lowest. Starbucks has 36 analysts cover it, with 11 having strong buy ratings, 11 having buys, 13 having hold ratings and one analyst has a strong sell on the stock.

BMO Capital Markets raised their 12-month price target on Starbucks to $140, up from $125, and reiterated their outpeform rating on the stock. They add, “we gain confidence in SBUX’s US sales and overall margin potential, which should continue creating upside opportunities for estimates over next 12+ months.”

The biggest takeaway BMO has from Starbucks earnings is that their US momentum will continue into the year end. This quarter their US growth accelerated 4% and fourth quarter guidance implies another 2%. They say, “We are encouraged to see SBUX hold onto its check gains and realize record food attachment rates despite the normalizing operating environment.”

Below you can see BMO’s updated fourth quarter, 2021, and 2022 estimates.


Information for this briefing was found via Sedar and Refinitiv. The author has no securities or affiliations related to this organization. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security. The author holds no licenses.

Leave a Reply

Video Articles

Teck Resources Q1 Earnings: Defying Copper Industry Weakness

Equinox Ups Its Offer For Calibre: Investors Said No!

First Quantum Q1 Earnings: Copper Major Still Bleeding Cash

Recommended

Cardiol Sees First Patient Enrolled Under Phase III MAVERIC Clinical Trial

Rua Gold Hits 13.3 g/t Gold, 8.1% Antimony Over 1.25 Metres At Auld Creek

Related News

Beyond Meat: Analysts Lower Price Targets Following Disappointing Earnings

Beyond Meat (NASDAQ: BYND) has been a laggard this year, with its year-to-date performance currently...

Sunday, May 16, 2021, 02:13:00 PM

Canopy Growth: Canaccord Reduces Target To $6, Anticipates Further Cost Cutting

Canopy Growth (TSX: WEED) is expected to report its fiscal fourth-quarter financial results tomorrow morning....

Thursday, May 26, 2022, 04:32:00 PM

Canopy: BofA Slashes Price Target To $19

On November 19th, Bank Of America terminated coverage on Tilray and Aurora Cannabis citing a...

Saturday, November 27, 2021, 12:43:00 PM

Amazon: Analysts Expect $115.1 Billion In Q2 Revenue

Amazon.com Inc (NASDAQ: AMZN) will be reporting its second quarter financial results today after markets...

Thursday, July 29, 2021, 11:24:00 AM

Organigram: Consensus Price Target Falls To $3.55

On November 23rd, Organigram Holdings (TSX: OGI) announced its fourth quarter fiscal 2021 results. The...

Sunday, November 28, 2021, 01:18:00 PM